Keyword Analysis & Research: ianalumab

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
ianalumab1.880.86643839

Keyword Research: People who searched ianalumab also searched

Keyword CPC PCC Volume Score
ianalumab1.210.4501960

Search Results related to ianalumab on Search Engine

  • Ianalumab - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Ianalumab

    WEBIanalumab ( INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II / III trials.

    DA: 79 PA: 86 MOZ Rank: 33

  • Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) …

    ashpublications.org

    https://ashpublications.org/blood/article/142/Supplement%201/5427/499591/Ianalumab-a-Novel-Anti-B-Cell-Activating-Factor

    WEBNov 28, 2023 · Ianalumab is a fully human mAb that targets BAFF-R. It has a novel dual mechanism of action: blockade of BAFF-R-mediated signaling and potent depletion of B cells mediated by antibody-dependent cellular cytotoxicity.

    DA: 81 PA: 88 MOZ Rank: 77

  • Safety and efficacy of subcutaneous ianalumab (VAY736) in …

    thelancet.com

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02251-0/fulltext

    WEBNov 30, 2021 · A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy. This dose-finding trial aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren's syndrome. Methods.

    DA: 51 PA: 12 MOZ Rank: 77

  • Safety and efficacy of subcutaneous ianalumab (VAY736) in

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/34861168/

    WEBJan 8, 2022 · A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy. This dose-finding trial aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren's syndrome.

    DA: 22 PA: 95 MOZ Rank: 16

  • Ianalumab - an overview | ScienceDirect Topics

    sciencedirect.com

    https://www.sciencedirect.com/topics/medicine-and-dentistry/ianalumab

    WEBIanalumab (previously known as VAY736) is a novel BAFF-targeting antibody, which was recently evaluated in patients with pSS [80]. Ianalumab prevents BAFF signaling through its receptor BAFF-R and in addition depletes BAFF-R expressing B-cells through antibody-dependent cellular cytotoxicity.

    DA: 87 PA: 54 MOZ Rank: 50

  • A Study of Ianalumab (VAY736) in Patients With Primary

    novartis.com

    https://www.novartis.com/clinicaltrials/study/nct05885555

    WEBMar 26, 2024 · The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA. This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ...

    DA: 4 PA: 67 MOZ Rank: 41

  • Phase 3 Study to Evaluate Ianalumab on Top of Standard-of ... - Novartis

    novartis.com

    https://www.novartis.com/clinicaltrials/study/nct05624749

    WEBApr 12, 2024 · The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

    DA: 63 PA: 38 MOZ Rank: 53

  • Treatment of primary Sjögren’s syndrome with ianalumab …

    bmj.com

    https://ard.bmj.com/content/78/5/641

    WEBObjectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) in a double-blind, placebo-controlled, phase II, …

    DA: 11 PA: 55 MOZ Rank: 57

  • Research in Brief - The Lancet Rheumatology

    thelancet.com

    https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00398-2/fulltext

    WEBThe novel B-cell-depleting biological drug ianalumab has shown promise in the treatment of primary Sjögren's syndrome in a phase 2b, dose-finding trial by Simon Bowman and colleagues. 190 patients with moderate-to-severe disease activity and symptom severity were randomly assigned (1:1:1:1) to receive placebo (n=49) or ianalumab 5 mg (n=47), …

    DA: 37 PA: 83 MOZ Rank: 53

  • Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S0006497123120283

    WEBNov 2, 2023 · Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic …

    DA: 85 PA: 9 MOZ Rank: 94